6 news items
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BNTX
GMAB
1 Jun 24
will continue to evaluate these data to inform further development of acasunlimab including a planned Phase 3 trial as we remain committed to investigate
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BNTX
GMAB
1 Jun 24
to evaluate these data to inform further development of acasunlimab including a planned Phase 3 trial as we remain committed to investigate acasunlimab
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
GMAB
14 May 24
with AbbVie, we are committed to advancing and evolving the robust development program evaluating epcoritamab, as a monotherapy and in combination, across B
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
cancer, genitourinary cancer, hematology-oncology and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to extend and improve patients' lives
rn4kwzwycxyc3yw7na7hv0fbcwyak10p9k50zio1idk80
GMAB
PFE
29 Apr 24
cancer, genitourinary cancer, hematology-oncology and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating
- Prev
- 1
- Next